Why the study?
Does atrial resynchronization therapy reduce symptoms or improve prognosis in patients with HFPEF and atrial dyssynchrony?
Does atrial resynchronization therapy reduce symptoms or improve prognosis in patients with HFPEF and atrial dyssynchrony?
Answers are grounded in this paper and cite their sources.
Atrial resynchronization therapy represents an intriguing hypothetical concept for treating HFPEF and preventing atrial fibrillation that warrants further investigation in randomized clinical trials.
This editorial refers to ‘Atrial dyssynchrony syndrome: an overlooked phenomenon and a potential cause of “diastolic” heart failure’, by J.-C. Eicher et al., published in this issue on pages 248–258. Heart failure with preserved ejection fraction (HFPEF) is a common problem with a large impact for affected patients and healthcare providers. It is estimated that HFPEF is as common as heart failure associated with depressed systolic function.1 There are few proven treatment options for patients with HFPEF.2 Patients are treated with heart failure drugs such as beta-adrenergic receptor antagonists, angiotensin-converting enzyme inhibitors, or angiotensin II type 1 receptor antagonists without clinical evidence for reduction of symptoms or hard endpoints such as mortality or heart failure hospitalizations.3 The lack of effective pharmacological therapy increases the demand for alternative treatment options, including cardiac device therapy.4 In this issue of the European Journal of Heart Failure, Eicher et al. show a new mechanism contributing to HFPEF and atrial fibrillation (AF) in selected patients.5 Atrial dyssynchrony has been seen in patients with atrial pacing, but prevalence in patients in sinus rhythm had not been thoroughly studied. In an elegant approach, Eicher et al. went from an intriguing case report to a systematic analysis of all admitted patients with HFPEF, and identified seven patients with a typical pattern of delayed left atrial (LA) systole and thus shortened LA emptying and increased filling pressures.5 These patients were investigated with right heart catheterization, showing post-capillary pulmonary hypertension and interatrial conduction delay. Electrophysiological testing revealed severe interatrial conduction delay that could be reduced to normal values with LA pacing in the coronary sinus. If this new therapeutic concept that could be termed ‘atrial resynchronization therapy’ will lead to a reduction of symptoms or improvement of prognosis needs to be prospectively studied. Heart failure with preserved ejection fraction often occurs in the setting of hypertension, as was the case in the present study, and is a major contributor to the development of AF due to elevated atrial pressures, with concomitant stretch electrical and structural remodelling being the driving mechanisms.6 Atrial remodelling includes conduction disturbances which set the stage for atrial dyssynchrony. This may then lead to a further increase in filling pressures and a higher probability of AF, both contributing to a further deterioration of atrial structural remodelling (Figure 1). To complete the vicious circle, AF often leads to worsening heart failure symptoms, especially in patients with disturbed diastolic filling. In addition, although there exists conflicting evidence about the prognostic importance of AF in heart failure, several studies suggest that AF is also associated with an impaired outcome7in HFPEF patients.8 Prevention of AF therefore may be of prognostic significance, although especially in this group of patients maintenance of sinus rhythm is cumbersome.9,10 The value of the study be Eicher et al. lies in the fact that it suggests new treatment avenues. Device therapy could be used to treat selected patients with HFPEF. Recent data have supported the use of cardiac resynchronization therapy in patients with left bundle branch block and withoutt severely depressed systolic function.11 The treatment of atrial dyssynchrony with biatrial pacing might increase diastolic filling and prevent LA contractions against a closed mitral valve, as has been shown in preliminary data from Eicher et al.5 An even more simple method could be atrial septal pacing or pacing in the great cardiac vein that could diminish interatrial dyssynchrony with one atrial lead. As of yet, there are no pacemakers with connections for two atrial leads, and one wonders if they will become available in the near future. Using a Y connection has the disadvantages of not being able to steer leads independently and higher energy consumption due to lower impedance and pacing above the threshold of the worst lead. Using fewer electrodes has the advantage of a lesser chance for complications such as dislocations or related to vascular access. The atrial dyssynchrony syndrome is an interesting hypothetical concept that requires more evidence before it can be widely accepted in clinical practice. The effectiveness of atrial resynchronization therapy needs to be established in randomized trials. Furthermore, it has not been convincingly shown that reverse atrial remodelling can occur to the same extent as ventricular reverse remodelling.12,13 Interestingly, atria appear to react much faster and more strongly to stretch due to dilatation as compared with ventricles.14 Structural remodelling can thus progress faster to a stage where it is irreversible. Atrial conduction delay is probably caused by atrial fibrosis that might be impossible to repair with the currently available treatments. Left ventricular reverse remodelling can occur with cardiac resynchronization therapy with normalization of cardiac function in a subgroup of patients. Ventricular dyssynchrony in these ‘super-responders’ is characterized by reduced systolic function with preserved contractile reserve but not a large amount of interstitial fibrosis characterized by severere diastolic dysfunction.15The regenerative capacity of cardiac myocytes is limited and there is no literature on this phenomenon in atria. Fibrosis can be interstitial due to stimulation of resident (myo)fibroblasts to increase extracellular matrix deposition. Fibrosis is also caused by replacement of myocytes lost to cell death due to, for example, apoptosis. Whereas interstitial fibrosis might be amenable to antifibrotic treatments such as aldosterone receptor antagonists, replacement fibrosis cannot be expected to be improved without myocyte regeneration by resident or transient cardiac progenitor cells. If atrial resynchronization therapy actually leads to improvement of HFPEF or prevention of atrial fibrillation remains to be seen. It might be effective in a subset of patients with HFPEF but, in the absence of other proven therapy, any new treatment concept for these patients is heralded.
No takes yet. Share an insight, caveat, or question.
Maass et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: